India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push

MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai